This study aims to answer the research question what are the prevalence and comparative safety of adverse pregnancy, offspring, and maternal outcomes in women exposed to Paxlovid during pregnancy? The primary study objective is to estimate the birth prevalence, prevalence ratio, and prevalence difference of the following adverse pregnancy, offspring, and maternal outcomes in women who are exposed to Paxlovid during pregnancy compared with those in women who are exposed to molnupiravir, where available, during pregnancy or to neither Paxlovid nor molnupiravir during pregnancy: spontaneous abortion, elective termination, stillbirth, preterm delivery (pregnancy outcomes), major congenital malformations, intrauterine growth retardation/small for gestational age (offspring outcomes), gestational diabetes, postpartum haemorrhage, maternal death (maternal outcomes). The study will focus on pregnant women. Within this population, there will be a descriptive analysis and comparative analyses. Molnupiravir, an antiviral with a similar recommended usage, will be used as an active comparator in the data sources in which it is available, other drugs may be incorporated as active comparators as more information becomes available. A second comparator group is included in the study: individuals with COVID‑19 unexposed to any study medication. This PASS will make secondary use of several data sources from electronic health records and/or claims data in European countries that have the ability to capture Paxlovid exposure and where the target populations, study outcomes, and key covariates can be ascertained.